--- title: About Simsen Diagnostics | Our story and mission description: Born from Swedish research, Simsen Diagnostics makes ultra-sensitive ctDNA detection accessible worldwide. Learn about our mission, milestones and team. --- [Skip to the main content.](https://simsendiagnostics.com/company-about#main-content) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) [![Simsen logotype](https://simsendiagnostics.com/hs-fs/hubfs/SD_logo%20medium-2.png?width=588&height=164&name=SD_logo%20medium-2.png "Simsen logotype")](https://simsendiagnostics.com?hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) Search [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKsUtTH%2Fhx%2FEI7DJfMM3Rv0La5HxW6rpheB6bMk%2B2oiuvPtfB0p%2B04AIUgsAvyIxVVrPrlOffQTVtyQEhGVxDOa444dH1NAFntv40l20svotKrSkR7vzNyVfr3WILJO6fnWifoSzUmzuXEn32QXStfq8z%2B79DQ4RrwFx%2FbdybyToHDkNs9BxhLIvTVN%2FS1I1QHHFva%2B&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) Toggle Menu Search Toggle Menu [![Request a conversation](https://hubspot-no-cache-eu1-prod.s3.amazonaws.com/cta/default/25734893/interactive-412216133822.png)](https://simsendiagnostics.com/hs/cta/wi/redirect?encryptedPayload=AVxigLKsUtTH%2Fhx%2FEI7DJfMM3Rv0La5HxW6rpheB6bMk%2B2oiuvPtfB0p%2B04AIUgsAvyIxVVrPrlOffQTVtyQEhGVxDOa444dH1NAFntv40l20svotKrSkR7vzNyVfr3WILJO6fnWifoSzUmzuXEn32QXStfq8z%2B79DQ4RrwFx%2FbdybyToHDkNs9BxhLIvTVN%2FS1I1QHHFva%2B&webInteractiveContentId=412216133822&portalId=25734893&hsLang=en) - [PLATFORM](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Methodology](https://simsendiagnostics.com/platform-methodology) - [Find your approach](https://simsendiagnostics.com/find-your-approach) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) - [Solutions](https://simsendiagnostics.com/solutions-overview) - [EVIDENCE](https://simsendiagnostics.com/evidence-hub) - [Publications](https://simsendiagnostics.com/evidence-publications) - [Paediatric solid tumours](https://simsendiagnostics.com/evidence-paediatric-solid-tumours) - [CNS tumours & CSF ctDNA](https://simsendiagnostics.com/evidence-cns-csf-ctdna) - [White papers](https://simsendiagnostics.com/evidence-white-paper-ctdna-trials) - [COMPANY](https://simsendiagnostics.com/company-about) - [About us](https://simsendiagnostics.com/company-about) - [Team](https://simsendiagnostics.com/company-team) - [Contact us](https://simsendiagnostics.com/company-contact) - [News](https://simsendiagnostics.com/news) - [RESOURCES](https://simsendiagnostics.com/resources-hub) - [Sample collection guides](https://simsendiagnostics.com/resources-sample-collection-guides) - [Baseline kit guide](https://simsendiagnostics.com/baseline-collection-kit) - [Follow-up kit guide](https://simsendiagnostics.com/resources-followup-collection-kit) [For clinical trials Pharma and CROs Validate MRD endpoints, cut trial-arm cost, build EU regulatory readiness. Design a trial assay →](https://simsendiagnostics.com/solutions-trials?hsLang=en) [For research and labs Translational oncology See signal in paediatric and early-stage samples your current platform misses. Send samples or run SiMSen-Seq in-house. See the signal →](https://simsendiagnostics.com/solutions-research?hsLang=en) [For clinics Premium oncology monitoring Detect minimal residual disease ahead of imaging. Logistics across the EU, UK and EEA. Detect relapse earlier →](https://simsendiagnostics.com/solutions-clinic?hsLang=en) [Home](https://simsendiagnostics.com?hsLang=en) / Company / About About Simsen # Built so your team can act on cancer *sooner*. Simsen Diagnostics exists for one reason: to put ultra-sensitive ctDNA within reach of the teams treating and studying cancer, in Europe, on your terms. This page is the why behind that, and what it means for the work you do. Our mission ### Give every oncology team the signal they need, early enough to use it. We make ultra-sensitive sequencing easy, so healthcare and pharmaceutical leaders can monitor cancer with precision and make data-driven decisions for better patient outcomes. Our vision ### A future where cancer is a curable disease. By advancing personalised ctDNA monitoring, we aim to give clinicians and researchers the tools to detect, monitor and treat cancer with unmatched precision, bringing the field closer to a world free from its burden.   Why we exist ## The signal was always there. The *access* was not. Circulating tumour DNA tells you whether disease is responding, residual or returning, often months before imaging can. The problem was never the biology. It was getting that sensitivity into the hands of the teams who need it, without sending samples across the world or rebuilding your lab. Simsen was founded in Gothenburg in 2020 by the inventors of SiMSen-Seq, Professor Anders Ståhlberg and Professor Tony Godfrey, together with Professor Mikael Kubista and GU Ventures. The method had already been published in Nature Protocols. The company exists to turn that science into a service teams across Europe can actually use. SiMSen-Seq drives error-corrected sequencing down to parts-per-million sensitivity. For your patients and your studies, that means catching residual disease and early relapse when the window to act is still open, not after. We deliver it your way. Send us samples and receive clear, interpreted reports from our lab, or run our personalised panels in your own laboratory with LabSuite. Either route, you keep control and you keep the relationship with a European partner working in your time zone. Today we work with research hospitals, private cancer clinics and pharmaceutical companies, with a clear growth plan and further European expansion underway. The mission has not changed since day one: earlier, more certain answers for the people you treat and study. Simsen at a glance 3–5 ppm Residual ctDNA detected three days after pancreatic surgery (ongoing study) 9 months ctDNA lead time over clinical relapse in ALK-driven neuroblastoma (Ek et al., 2024) 2020 Founded by the inventors of SiMSen-Seq, together with Prof. Kubista and GU Ventures EU Based at AstraZeneca BioVentureHub, Mölndal. Quality system compliant with ISO 15189 and ISO 9001; accreditation in progress. WHAT YOU GET FROM WORKING WITH US   ## Five things we hold ourselves to. The same five promises run through every page on this site, retold in your language on each Solutions page. Here is the short version. 1 ### Sensitivity Parts-per-million detection, so you see disease while there is still time to act. 2 ### Flexibility Full service or run it in-house with LabSuite. Your samples, your choice. 3 ### Clinical insight Clear, interpreted reporting, not just raw data dumped on your desk. 4 ### Transparency Honest about methodology and limits, with access to the data behind every result. 5 ### Partnership A European team in your time zone, open to co-publication and long-term work. How we got here ## From a published method to a working partner. A short history of the milestones behind the service you would be working with. 1. 2017 ### SiMSen-Seq published The SiMSen-Seq method for ultra-sensitive, error-corrected sequencing is published in Nature Protocols. 2. 2020 ### Simsen is founded Inventors Prof. Anders Ståhlberg and Prof. Tony Godfrey incorporate the company with Prof. Mikael Kubista and GU Ventures to commercialise the method. 3. 2021 ### Business begins A 50 MSEK Vinnova grant is awarded, the first employee is hired, further patents are filed and a lab is established at Sahlgrenska Science Park. 4. 2022 ### First customers Research hospitals, international diagnostics companies and pharmaceutical companies sign on. 5. 2023 ### Move to BioVentureHub Office and lab move to AstraZeneca's BioVentureHub in Mölndal, on the edge of Gothenburg, Sweden. 6. 2024 ### Growth More customers sign on, including the first private cancer clinic. A comprehensive QMS and GDPR framework is built, and a growth plan with international expansion begins. 7. 2026 ### Where we are now Cancer centres across the Nordics, the UK and Southern Europe are choosing Simsen for ctDNA analysis, from full-service monitoring to piloting testing in their own labs. As demand grows, we are applying for ISO 15189 accreditation as well as ISO 9001 and 14001 certifications, and building the capacity to give every customer the same fast, reliable turnaround they rely on us for today. TALK TO US   ## Want to know if this fits your samples? A real human, in CET/CEST time zone, who has run samples like yours. Tell us about your trial, your patients, or your lab.   [Request a conversation](https://simsendiagnostics.com/start-a-conversation?hsLang=en) [Meet the team](https://simsendiagnostics.com/company-team?hsLang=en)   ![full_lockup_white_CMYK kopia](https://simsendiagnostics.com/hs-fs/hubfs/full_lockup_white_CMYK%20kopia.png?width=166&height=45&name=full_lockup_white_CMYK%20kopia.png) **Visiting and postal address:** Pepparedsleden 1 431 53 Mölndal, Sweden **Shipping address:** c/o AstraZeneca R&D Mölndal Pepparedsleden 3 431 53 Mölndal, Sweden PLATFORM PLATFORM - [Platform overview](https://simsendiagnostics.com/platform) - [Why Simsen](https://simsendiagnostics.com/why-simsen) - [Our technology](https://simsendiagnostics.com/platform-our-technology) - [Delivered your way](https://simsendiagnostics.com/both-delivery-models) SOLUTIONS SOLUTIONS - [For clinical trials](https://simsendiagnostics.com/solutions-trials) - [For research and labs](https://simsendiagnostics.com/solutions-research) - [For clinics](https://simsendiagnostics.com/solutions-clinic) - [Solutions overview](https://simsendiagnostics.com/solutions-overview) COMPANY COMPANY - [About](https://simsendiagnostics.com/company-about) - [News](https://simsendiagnostics.com/news) - [Team](https://simsendiagnostics.com/company-team) - [Contact](https://simsendiagnostics.com/company-contact) - [Privacy policy](https://simsendiagnostics.com/legal-privacy-policy) - [Cookie Policy](https://simsendiagnostics.com/legal-cookie-policy) - [Terms of use](https://simsendiagnostics.com/legal-terms-of-use) © 2026 Simsen Diagnostics AB, All rights reserved. [Linkedin](https://www.linkedin.com/company/simsendiagnostics) Return to top